We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Pacira settlement could have ripple effects on a range of FDA issues far beyond promotional claims

David M. Fox

David M. Fox,

Washington, D.C.

Meredith Manning

Meredith Manning,

Washington, D.C.

Nancy M. Parsons

Nancy M. Parsons,

Washington, D.C.

07 January 2016
We continue to examine the Pacira case documents and give this settlement in-depth thought across all areas of our FDA regulatory practice. As we hinted in our December 17th post, we believe this case could have significant reach. Most obviously, there are implications for the advertising and promotion of drug products, and undoubtedly, FDA will try to limit the applicability of the settlement. At minimum, the case influences the interpretation of labeling for drugs similarly situated to Exparel – i.e., they have: a) a broad indication based on pivotal trials that focus on a more narrow patient population or disease sub-type or stage; b) favorable or ambiguous labeling and regulatory history on point; and c) a medical and scientific argument (and ideally FDA guidance) that supports extrapolation from clinical study populations to broader populations. Less obviously but just as important, there also may be implications for clinical development strategies and labeling negotiations. If this case signals a change in the Agency’s interpretation of a product’s indication, it could also weigh heavily in life cycle plans, where the scope of a product’s approval can affect opportunities for future market exclusivity and could even impact the scope of the patents that may be listed in FDA’s Orange Book for a given drug product.
David M. Fox

David M. Fox,

Washington, D.C.

Meredith Manning

Meredith Manning,

Washington, D.C.

Nancy M. Parsons

Nancy M. Parsons,

Washington, D.C.

EMA to Revise Herbal Medicines Guideline

On 1 September 2016, the European Medicines Agency ("EMA") opened for public consultation a Draft revision to its Guideline on the assessment of clinical safety and efficacy in the...

08 September 2016
Loading data